These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12438957)

  • 41. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
    Kilic ZM; Kuran S; Akdogan M; Cicek B; Oguz D; Odemis B; Sasmaz N
    Adv Ther; 2008 Mar; 25(3):190-200. PubMed ID: 18385953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.
    Bock CT; Tillmann HL; Torresi J; Klempnauer J; Locarnini S; Manns MP; Trautwein C
    Gastroenterology; 2002 Feb; 122(2):264-73. PubMed ID: 11832441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Lamivudine as prophylaxis against hepatitis B virus reinfection following orthotopic liver transplantation].
    Zheng S; Wu J; Wang W; Huang D; Liang T; Lu A
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(7):445-8. PubMed ID: 12133511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis.
    Kitay-Cohen Y; Ben-Ari Z; Tur-Kaspa R; Fainguelernt H; Lishner M
    Transplantation; 2000 Jun; 69(11):2382-3. PubMed ID: 10868644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
    Ben-Ari Z; Broida E; Kittai Y; Chagnac A; Tur-Kaspa R
    Am J Gastroenterol; 2000 Dec; 95(12):3579-83. PubMed ID: 11151895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
    Perrillo RP; Wright T; Rakela J; Levy G; Schiff E; Gish R; Martin P; Dienstag J; Adams P; Dickson R; Anschuetz G; Bell S; Condreay L; Brown N;
    Hepatology; 2001 Feb; 33(2):424-32. PubMed ID: 11172345
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.
    Mutimer D; Dusheiko G; Barrett C; Grellier L; Ahmed M; Anschuetz G; Burroughs A; Hubscher S; Dhillon AP; Rolles K; Elias E
    Transplantation; 2000 Sep; 70(5):809-15. PubMed ID: 11003363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Precore and contiguous regions of hepatitis B virus in liver transplantation for end-stage hepatitis B.
    Laskus T; Rakela J; Steers JL; Wiesner RH; Persing DH
    Gastroenterology; 1994 Dec; 107(6):1774-80. PubMed ID: 7958691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
    Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
    Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation.
    Wang SS; Chou NK; Chi NH; Hsu RB; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Lai MY; Chu SH
    Transplant Proc; 2006 Sep; 38(7):2138-40. PubMed ID: 16980024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.
    Benhamou Y; Katlama C; Lunel F; Coutellier A; Dohin E; Hamm N; Tubiana R; Herson S; Poynard T; Opolon P
    Ann Intern Med; 1996 Nov; 125(9):705-12. PubMed ID: 8929003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection.
    Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V
    Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B.
    Akyildiz M; Gunsar F; Ersoz G; Karasu Z; Ilter T; Batur Y; Akarca U
    Dig Dis Sci; 2007 Dec; 52(12):3444-7. PubMed ID: 17431777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin.
    Lo CM; Cheung ST; Ng IO; Liu CL; Lai CL; Fan ST
    Liver Transpl; 2004 Apr; 10(4):557-63. PubMed ID: 15048802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
    Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
    Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.